The role of CB2 receptors in oxLDL-induced apopotosis and atherogenesis

CB2受体在oxLDL诱导的细胞凋亡和动脉粥样硬化形成中的作用

基本信息

  • 批准号:
    7128044
  • 负责人:
  • 金额:
    $ 21.9万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2006
  • 资助国家:
    美国
  • 起止时间:
    2006-08-15 至 2009-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Our laboratory has been engaged in studies to determine the signal transduction pathway by which naturally occurring oxysterols induce apoptosis in various vascular cells, particularly macrophages. Our published results indicate that arachidonyl esters of these oxysterols are second messengers of the apoptotic response. In an effort to understand the mechanism by which these compounds entrain apoptosis we have begun to examine the hypothesis that arachidonyl oxysterols produce these effects via the cannabinoid 2 (CB2) receptor. Preliminary findings, presented in this proposal, of a loss of the apoptotic response to oxysterol treatment in various cell models defective in CB2 signaling are consistent with this hypothesis. Other studies from our laboratory indicate that one of the physiologically significant consequences of macrophage apoptosis in response to oxysterols is as a protective mechanism against atherosclerosis. This raises the possibility that CB2 signaling of apoptosis in macrophages may serve as one of the signaling pathways of this anti-atherosclerotic effect. To test these ideas regarding the mechanism and physiological significance of arachidonyl oxysterol signaling of apoptosis in macrophages we propose the following specific aims: 1) Determine if arachidonyl oxysterols can induce apoptosis in macrophages. 2) Determine if arachidonyl oxysterols can bind to cannabinoid receptors and modulate their activity. 3) Examine the role of the CB2 receptor in the development of atherosclerosis in mouse models. The results from this investigation may expand our understanding of the link between cannabinoid signaling mechanisms and the mechanisms regulating apoptosis in macrophages. They may also provide new pharmacologically exploitable targets for the development of novel pharmaceuticals for treatment of atherosclerosis.
描述(由申请人提供):我们的实验室一直在进行研究,以确定天然存在的氧固醇诱导各种血管细胞,特别是巨噬细胞凋亡的信号转导途径。我们发表的研究结果表明,这些氧化固醇的花生四烯酸酯是凋亡反应的第二信使。为了理解这些化合物诱导细胞凋亡的机制,我们已经开始研究花生四烯酸氧化甾醇通过大麻素2(CB 2)受体产生这些作用的假设。初步的调查结果,在这个建议中,在CB2信号传导缺陷的各种细胞模型中对氧固醇治疗的凋亡反应的损失与这一假设一致。我们实验室的其他研究表明,巨噬细胞凋亡对氧化固醇的生理学意义的后果之一是作为一种保护机制,防止动脉粥样硬化。这提高了巨噬细胞中细胞凋亡的CB 2信号传导可能作为这种抗动脉粥样硬化作用的信号传导途径之一的可能性。为了验证这些关于花生四烯酸氧化固醇信号转导在巨噬细胞中的凋亡的机制和生理意义的想法,我们提出了以下具体目标:1)确定花生四烯酸氧化固醇是否可以诱导巨噬细胞中的凋亡。2)确定花生四烯酸氧化固醇是否可以与大麻素受体结合并调节其活性。3)研究CB2受体在小鼠模型动脉粥样硬化发展中的作用。这项研究的结果可能会扩大我们对大麻素信号传导机制和调节巨噬细胞凋亡机制之间联系的理解。它们还可以为开发用于治疗动脉粥样硬化的新药提供新的可开发的靶点。

项目成果

期刊论文数量(6)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Cannabinoid Receptor Type 2 (CB2) Dependent and Independent Effects of WIN55,212-2 on Atherosclerosis in Ldlr-null Mice.
  • DOI:
    10.12970/2311-052x.2015.03.02.2
  • 发表时间:
    2015-07
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Netherland-Van Dyke C;Rodgers W;Fulmer M;Lahr Z;Thewke D
  • 通讯作者:
    Thewke D
Stimulation of Akt poly-ubiquitination and proteasomal degradation in P388D1 cells by 7-ketocholesterol and 25-hydroxycholesterol.
  • DOI:
    10.1016/j.abb.2009.05.004
  • 发表时间:
    2009-07-01
  • 期刊:
  • 影响因子:
    3.9
  • 作者:
    Liu J;Netherland C;Pickle T;Sinensky MS;Thewke DP
  • 通讯作者:
    Thewke DP
Cannabinoid receptor type 2 (CB2) deficiency alters atherosclerotic lesion formation in hyperlipidemic Ldlr-null mice.
  • DOI:
    10.1016/j.atherosclerosis.2010.07.060
  • 发表时间:
    2010-11
  • 期刊:
  • 影响因子:
    5.3
  • 作者:
    Netherland, Courtney D.;Pickle, Theresa G.;Bales, Alicia;Thewke, Douglas P.
  • 通讯作者:
    Thewke, Douglas P.
Rimonabant is a dual inhibitor of acyl CoA:cholesterol acyltransferases 1 and 2.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DOUGLAS P THEWKE其他文献

DOUGLAS P THEWKE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DOUGLAS P THEWKE', 18)}}的其他基金

Modulation of atherosclerosis by cannabinoid type 2 receptor
大麻素 2 型受体调节动脉粥样硬化
  • 批准号:
    8432536
  • 财政年份:
    2013
  • 资助金额:
    $ 21.9万
  • 项目类别:
Regulation of stearoyl-CoA desaturases by oleate
油酸对硬脂酰辅酶A去饱和酶的调节
  • 批准号:
    6524278
  • 财政年份:
    2001
  • 资助金额:
    $ 21.9万
  • 项目类别:
Regulation of stearoyl-CoA desaturases by oleate
油酸对硬脂酰辅酶A去饱和酶的调节
  • 批准号:
    6781750
  • 财政年份:
    2001
  • 资助金额:
    $ 21.9万
  • 项目类别:
Regulation of stearoyl-CoA desaturases by oleate
油酸对硬脂酰辅酶A去饱和酶的调节
  • 批准号:
    6328436
  • 财政年份:
    2001
  • 资助金额:
    $ 21.9万
  • 项目类别:
Regulation of stearoyl-CoA desaturases by oleate
油酸对硬脂酰辅酶A去饱和酶的调节
  • 批准号:
    6613483
  • 财政年份:
    2001
  • 资助金额:
    $ 21.9万
  • 项目类别:

相似海外基金

Dissecting the Role of Arachidonic Acid Metabolic Pathways Involved in Resolution Versus Progression of PM-Induced Cardiometabolic Toxicity
剖析花生四烯酸代谢途径在 PM 诱导的心脏代谢毒性的消退与进展中的作用
  • 批准号:
    10716093
  • 财政年份:
    2023
  • 资助金额:
    $ 21.9万
  • 项目类别:
Lipid peroxidation- and pyroptosis-induced tissue factor activation in pathogen-induced blood coagulation
病原体诱导的血液凝固中脂质过氧化和焦亡诱导的组织因子激活
  • 批准号:
    10571353
  • 财政年份:
    2023
  • 资助金额:
    $ 21.9万
  • 项目类别:
Lipid Receptor GPR31 as a Target for Anti-Thrombotic and Stroke Therapy
脂质受体 GPR31 作为抗血栓和中风治疗的靶点
  • 批准号:
    10325956
  • 财政年份:
    2021
  • 资助金额:
    $ 21.9万
  • 项目类别:
Necroptosis Impairs Inflammation-Resolution Programs in Atherosclerosis
坏死性凋亡损害动脉粥样硬化的炎症消退程序
  • 批准号:
    9496529
  • 财政年份:
    2018
  • 资助金额:
    $ 21.9万
  • 项目类别:
Necroptosis Impairs Inflammation-Resolution Programs in Atherosclerosis
坏死性凋亡损害动脉粥样硬化的炎症消退程序
  • 批准号:
    10349539
  • 财政年份:
    2018
  • 资助金额:
    $ 21.9万
  • 项目类别:
Specialized pro-resolving mediators in atherosclerosis
动脉粥样硬化的专门促解决介质
  • 批准号:
    8566813
  • 财政年份:
    2013
  • 资助金额:
    $ 21.9万
  • 项目类别:
Specialized pro-resolving mediators in atherosclerosis
动脉粥样硬化的专门促解决介质
  • 批准号:
    8710340
  • 财政年份:
    2013
  • 资助金额:
    $ 21.9万
  • 项目类别:
Specialized pro-resolving mediators in atherosclerosis
动脉粥样硬化的专门促解决介质
  • 批准号:
    9092595
  • 财政年份:
    2013
  • 资助金额:
    $ 21.9万
  • 项目类别:
Specialized pro-resolving mediators in atherosclerosis
动脉粥样硬化的专门促解决介质
  • 批准号:
    9130230
  • 财政年份:
    2013
  • 资助金额:
    $ 21.9万
  • 项目类别:
12/15-lipoxygenase, Insulin-like Growth Factor-1 and Atherosclerosis
12/15-脂氧合酶、胰岛素样生长因子-1 和动脉粥样硬化
  • 批准号:
    8445021
  • 财政年份:
    2013
  • 资助金额:
    $ 21.9万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了